Immune booster shot aims to speed recovery after cord blood transplant
NCT ID NCT04707300
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether injecting special immune progenitor cells (HTLPs) can help the immune system recover faster after a cord blood transplant in adults with blood cancers. Ten participants will receive the injection alongside their transplant. The goal is to see if it is safe and if it speeds up T-cell recovery, which could lower infection risk and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Human T Lymphoid Progenitor (HTLP) cells
What this could lead to
If successful, this could lead to faster immune recovery after cord blood transplants, reducing infection risk and improving outcomes for blood cancer patients.
What could go wrong
This is a very small, early-phase trial (only 10 participants) testing safety and feasibility. The approach may not work or could cause severe graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hematology department / Necker Children's Hospital
RECRUITINGParis, Île-de-France Region, 75015, France
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Saint Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
IUCT Oncopole Toulouse
RECRUITINGToulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Service d'Hématologie et thérapie cellulaire / CHU of Bordeaux
RECRUITINGPessac, 33604, France
Contact Email: •••••@•••••